Wegovy vs Zepbound Cost Comparison 2026: Which Brand-Name GLP-1 Is Cheaper?

Both Wegovy and Zepbound are FDA-approved for chronic weight management, making this a cleaner head-to-head than most GLP-1 comparisons. Both are premium brand-name medications. Both have manufacturer self-pay programs. And both have drastically different real-world pricing depending on your insurance status, your chosen delivery format, and what tier you're on. Here's the full 2026 picture.

Head-to-head: every price path

The big 2026 shift: Wegovy pills

The most important development in the Wegovy vs. Zepbound cost question happened in January 2026, when Novo Nordisk launched the Wegovy pill — the first FDA-approved oral GLP-1 medication for weight management. Through NovoCare Pharmacy, the Wegovy pill is priced at $149/month for the 1.5mg and 4mg starter doses (through August 31, 2026) and $299/month for the 9mg and 25mg maintenance doses.

At $149/month, the Wegovy pill is the cheapest FDA-approved GLP-1 access point in the US. It undercuts every Zepbound pathway except insurance copays, beats brand-name Ozempic, and even competes with some compounded telehealth programs. For cost-sensitive patients who specifically want an FDA-approved medication, this changed the math overnight.

Side-by-side cost by dose tier

Wegovy wins on self-pay cost at every dose tier. That's a genuine change from 2024, when Zepbound was often positioned as the lower-cost self-pay option. The combination of Wegovy's flat $349/month pricing (versus Zepbound's dose-based tiering) and the new $149/month pill makes Wegovy the cheaper brand-name path in 2026.

With insurance: the coverage comparison

Commercial insurance pricing is where Wegovy and Zepbound look nearly identical. Both drugs have manufacturer savings card programs that cap out-of-pocket at $25/month for commercially insured patients who qualify, with savings up to $100/month for Zepbound and as low as $0/month for Wegovy.

The real difference is coverage itself — specifically, whether your plan's formulary includes the drug, and whether prior authorization is required.

The July 2026 Medicare BALANCE program is the most important pending change. Qualifying beneficiaries will get Zepbound KwikPen at $50/month copays through December 2026 under a negotiated $245/month drug price — making it meaningfully cheaper than any Wegovy pathway for Medicare-eligible patients with qualifying BMI and comorbidities.

Efficacy: where Zepbound fights back

If Wegovy wins on cost, Zepbound wins on clinical efficacy. This is the real tradeoff in the comparison:

• Wegovy (semaglutide): STEP trials showed average weight loss of approximately 15% of body weight over 68 weeks, with approximately 86% of participants losing at least 5%, 69% losing at least 10%, and 50% losing at least 15%.
• Zepbound (tirzepatide): SURMOUNT trials showed average weight loss of approximately 20–21% of body weight over 72 weeks at the highest dose — a meaningfully larger reduction.
• Head-to-head: The SURMOUNT-5 trial directly compared tirzepatide and semaglutide and found tirzepatide delivered significantly greater weight loss at 72 weeks.

In practical terms: on a 200-pound starting weight, semaglutide users can expect roughly 30 pounds lost on average, while tirzepatide users can expect roughly 40–42 pounds. That ~10-pound difference is the efficacy premium you're paying for with Zepbound.

True 12-month cost projections

Let's model the actual 12-month cost across every pathway, since GLP-1 therapy is a sustained treatment rather than a short-term intervention.

The compounded alternative

A growing share of patients skip the brand-name question entirely and opt for compounded semaglutide (the active ingredient in Wegovy) or compounded tirzepatide (the active ingredient in Zepbound) through licensed telehealth providers. Pricing is significantly lower than either brand-name pathway:

The tradeoff is regulatory: compounded medications are not FDA-approved, have not been evaluated by the FDA for safety or effectiveness, and exist in a period of active regulatory scrutiny. Whether the cost savings justify the uncertainty depends on individual risk tolerance.

Which one should you pick?

Here's the practical decision framework for 2026:

Pick Wegovy if...

• Cost is your top priority — especially if the new Wegovy pill at $149/month suits your dose.
• You have commercial insurance that covers Wegovy (many plans do, with $0–$25 copay).
• You prefer oral medication to weekly injections.
• You expect moderate weight loss goals (10–15% of body weight) and don't need tirzepatide's higher efficacy.

Pick Zepbound if...

• You have 50+ pounds to lose and want the highest-efficacy FDA-approved medication.
• You have commercial insurance that covers Zepbound at $25/month copay.
• You're Medicare-eligible with qualifying BMI — the July 2026 BALANCE program will cover Zepbound KwikPen at $50/month.
• You have obstructive sleep apnea — Zepbound is FDA-approved for this indication with broader Part D coverage.
• You've tried semaglutide and plateaued.

Consider the compounded alternative if...

• You don't have GLP-1 coverage and want the lowest total cost.
• You're comfortable with the regulatory uncertainty around compounded medications.
• You want access to oral tablet formulations for either active ingredient.

The bottom line

For self-pay patients in 2026, Wegovy is cheaper than Zepbound at every dose tier, and the Wegovy pill at $149/month is the cheapest FDA-approved GLP-1 in America. For insured patients, both drugs typically land at $25/month when covered — making the question medical rather than financial. For Medicare beneficiaries, the July 2026 BALANCE program will make Zepbound temporarily the most accessible option. And for patients seeking maximum efficacy regardless of cost, Zepbound's 20–21% weight loss vs. Wegovy's 15% remains the strongest argument for paying the premium.

Model your specific 12-month cost on every pathway with our True Monthly Cost Calculator, or see live provider pricing on the main comparison page.